All Stories

  1. Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease

    Article • Current Neuropharmacology, May 2015, Bentham Science Publishers

    Dr Nicola Simola

  2. Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?

    Article • Journal of Neurochemistry, July 2014, Wiley

    Dr Nicola Simola

  3. Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions

    Article • Journal of Neurochemistry, June 2014, Wiley

    Dr Nicola Simola

  4. Antagonism of Adenosine A 1 or A 2A Receptors Amplifies the Effects of MDMA on Glial Activation in the Mouse Brain: Relevance to Caffeine–MDMA Interactions

    Article • Journal of Caffeine Research, June 2014, Mary Ann Liebert Inc

    Dr Nicola Simola

  5. MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex

    Article • Psychopharmacology, April 2014, Springer Science + Business Media

    Dr Nicola Simola

  6. Perinatal asphyxia: CNS development and deficits with delayed onset

    Article • Frontiers in Neuroscience, March 2014, Frontiers

    Dr Nicola Simola

  7. l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

    Article • Experimental Neurology, March 2014, Elsevier

    Dr Nicola Simola

  8. Caffeine

    Article • January 2014, Springer Science + Business Media

    Dr Nicola Simola

  9. Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists

    Article • January 2014, Springer Science + Business Media

    Dr Nicola Simola

  10. Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: implications for the study of the affective properties of drugs of abuse

    Article • The International Journal of Neuropsychopharmacology, October 2013, Oxford University Press (OUP)

    Dr Nicola Simola

  11. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons

    Article • Experimental Neurology, September 2013, Elsevier

    Dr Nicola Simola

  12. Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats

    Article • Addiction Biology, August 2013, Wiley

    Dr Nicola Simola, PhD Cristina Cadoni

  13. Dopaminergic Treatments for Parkinson’s Disease: Light and Shadows

    Article • July 2013, Royal Society of Chemistry

    Dr Nicola Simola

  14. Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs

    Article • Journal of Caffeine Research, June 2013, Mary Ann Liebert Inc

    Dr Nicola Simola

  15. Role of movement in long-term basal ganglia changes: implications for abnormal motor responses

    Article • Frontiers in Computational Neuroscience, January 2013, Frontiers

    Dr Nicola Simola

  16. Microglial and astroglial activation by 3,4‐methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility

    Article • Journal of Neurochemistry, November 2012, Wiley

    Dr Nicola Simola

  17. Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective?

    Article • Experimental Neurology, September 2012, Elsevier

    Dr Nicola Simola

  18. Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: Comparison of the effects of different psychoactive drugs and relevance in drug-induced reward

    Article • Neuropharmacology, August 2012, Elsevier

    Dr Nicola Simola

  19. Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease

    Article • July 2012, Springer Science + Business Media

    Dr Nicola Simola

  20. A2AReceptor Antagonism and Dyskinesia in Parkinson’s Disease

    Article • Parkinson s Disease, January 2012, Hindawi Publishing Corporation

    Dr Nicola Simola

  21. Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity

    Article • Psychoneuroendocrinology, May 2011, Elsevier

    Dr Nicola Simola

  22. What Do You See as the Main Priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years?

    Article • Journal of Caffeine Research, March 2011, Mary Ann Liebert Inc

    Dr Nicola Simola

  23. Pharmacological Therapy of Parkinsons Disease: Current Options and New Avenues

    Article • Recent Patents on CNS Drug Discovery, November 2010, Bentham Science Publishers

    Dr Nicola Simola

  24. Can dietary substances protect against Parkinson's disease? The case of caffeine

    Article • Experimental Neurology, October 2010, Elsevier

    Dr Nicola Simola

  25. Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse

    Article • August 2010, Springer Science + Business Media

    Dr Nicola Simola

  26. Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins

    Article • Neurotoxicity Research, July 2010, Springer Science + Business Media

    Dr Nicola Simola

  27. A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug

    Article • Neuropharmacology, March 2010, Elsevier

    Dr Nicola Simola

  28. Role of Adenosine in the Basal Ganglia

    Article • January 2010, Elsevier

    Dr Nicola Simola

  29. Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats

    Article • Experimental Brain Research, December 2009, Springer Science + Business Media

    Dr Nicola Simola

  30. Influence of acute caffeine on 50-kHz ultrasonic vocalizations in male adult rats and relevance to caffeine-mediated psychopharmacological effects

    Article • The International Journal of Neuropsychopharmacology, June 2009, Oxford University Press (OUP)

    Dr Nicola Simola

  31. Assessment of Symptomatic and Neuroprotective Efficacy of Mucuna Pruriens Seed Extract in Rodent Model of Parkinson’s Disease

    Article • Neurotoxicity Research, February 2009, Springer Science + Business Media

    Dr Nicola Simola

  32. Anxiolytic-like Effects of N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides by Modulation of Translocator Protein Promoting Neurosteroid Biosynthesis

    Article • Journal of Medicinal Chemistry, August 2008, American Chemical Society (ACS)

    Dr Nicola Simola

  33. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6‐OHDA lesioned rat

    Article • Synapse, April 2008, Wiley

    Dr Nicola Simola

  34. Increase of dopamine D2High receptors in the striatum of rats sensitized to caffeine motor effects

    Article • Synapse, February 2008, Wiley

    Dr Nicola Simola

  35. Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6‐hydroxydopamine‐lesioned rats treated with D1 or D2 dopamine receptor agonists

    Article • Synapse, February 2008, Wiley

    Dr Nicola Simola

  36. Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats

    Article • Experimental Brain Research, November 2007, Springer Science + Business Media

    Dr Nicola Simola

  37. The 6-Hydroxydopamine model of parkinson’s disease

    Article • Neurotoxicity Research, September 2007, Springer Science + Business Media

    Dr Nicola Simola

  38. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats

    Article • European Journal of Pharmacology, July 2007, Elsevier

    Dr Nicola Simola

  39. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease

    Article • Journal of the Neurological Sciences, October 2006, Elsevier

    Dr Nicola Simola

  40. Sensitization to caffeine and cross-sensitization to amphetamine: Influence of individual response to caffeine

    Article • Behavioural Brain Research, September 2006, Elsevier

    Dr Nicola Simola, Prof Dr Omar Cauli

  41. Potentiation of amphetamine‐mediated responses in caffeine‐sensitized rats involves modifications in A2A receptors and zif‐268 mRNAs in striatal neurons

    Article • Journal of Neurochemistry, June 2006, Wiley

    Dr Nicola Simola

  42. New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists

    Article • Life Sciences, November 2005, Elsevier

    Dr Nicola Simola

  43. Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions

    Article • Experimental Neurology, September 2004, Elsevier

    Dr Nicola Simola